The WVU Rockefeller Neuroscience Institute (RNI) is providing patients greater statewide and regional access to a ...

Medicare Part B covers Leqembi for people with early Alzheimer's or mild cognitive impairment. Learn more about Leqembi and Medicare coverage here.

The federal Food & Drug Administration has approved two new Alzheimer’s medications that can offer people more time to live ...

Positrigo AG is raising $10 million for production and commercialization of its Neurolf brain positron emission tomography system in the U.S. The system hepls to diagnose Alzheimer’s disease. With ...

BofA has reinstated coverage of 11 large-cap pharmaceutical and biotech stocks, with Eli Lilly (LLY), Gilead (GILD) and Merck ...

For spouses who care for a partner with Alzheimer’s disease, every day brings a different battle and a new challenge. Every ...

Though there is uncertainty about Biogen's sales and profits improving significantly, investors can hold the stock given the potential of its new drugs.

BofA reinstated coverage of Biogen (BIIB) with a Neutral rating and $178 price target Biogen is “a cheaper name,” mostly because Leqembi for ...

What time is it?” Cheryl Miller asks her husband, John. He wants to answer, but his wife has already asked him that question ...

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...

Biogen (BIIB) was downgraded to hold by Jefferies over an anticipated royalty cut for Ocrevus, lackluster pipeline, and expected modest sales of Leqembi. Read more here.